Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a better drug leaflet curb unrealistic hopes about cancer medicines?

NCT ID NCT07061197

Knowledge-focused Sponsor: London School of Economics and Political Science Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This trial tests whether adding a structured key information section to patient leaflets helps people form more accurate expectations about a new cancer drug. Researchers will randomly assign about 2,100 UK adults to read one of three versions of a leaflet for tivozanib, a kidney cancer medicine. One version is the standard leaflet, another adds qualitative benefit statements, and a third adds quantitative benefit data. The study then measures how well each version shapes expectations and understanding of the drug's benefits and harms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Patient leaflet with a key information section (qualitative or quantitative benefit info)
What this could lead to
If it works, this could point toward clearer drug leaflets that help patients form more accurate expectations about benefits and risks.
What could go wrong
This is an online study with hypothetical scenarios, not a real clinical setting. Results may not reflect how patients actually use leaflets in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

2,101 people

The number who actually took part.

Started

Jul 2025

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults 18 years of age and older, * Adults fluent in English, * Adults residing in the United Kingdom (i.e., nationally representative sample of UK adults). Exclusion critera: \- Participants who do not meet all 3 inclusion criteria.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer

Contacts and locations

Locations

  • London School of Economics and Political Science

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.